Alzamend Neuro (ALZN) Liabilities and Shareholders Equity (2020 - 2026)
Alzamend Neuro's Liabilities and Shareholders Equity was $8.54 million in fiscal Q1 2027 (quarter ended Jul 31, 2026), up 35.0% from $6.33 million a year earlier and up 310.8% from the prior quarter.
Powered by 
Analysis
Alzamend Neuro (ALZN) Liabilities and Shareholders Equity (2020 - 2026) Analysis & Trends
At the end of FY2026 (ended Apr 30, 2026), Liabilities and Shareholders Equity at Alzamend Neuro came in at $2.08 million, down 54.8% from FY2025.
- Liabilities and Shareholders Equity shows a five-year compound annual growth rate of -6.5% (FY2021 to FY2026).
- In earlier fiscal years, Liabilities and Shareholders Equity was $4.6 million in FY2025 (+628.8%), $631,588 in FY2024 (-89.3%), $5.92 million in FY2023 (-59.2%) and $14.52 million in FY2022 (+398.4%).
- The fiscal Q1 2027 figure marks the highest quarterly Liabilities and Shareholders Equity since fiscal Q2 2023.
- Compared with a year earlier, Liabilities and Shareholders Equity was higher in six of the last eight quarters, with growth averaging 216.1%.
- The best year-over-year quarter for Liabilities and Shareholders Equity over five years was fiscal Q4 2025 (growth of 628.8%); the worst was fiscal Q3 2024 (a decline of 90.8%).
- Per Business Quant data, ALZN's Liabilities and Shareholders Equity in the three fiscal quarters before Q1 2027 was $2.08 million (Q4 2026), $4.04 million (Q3 2026) and $5.09 million (Q2 2026).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,165.22 Bn | 1,133.81 Bn | 19.71 Bn | 142.28 Bn |
| 2 | Johnson & Johnson | 646.28 Bn | 566.14 Bn | 17.30 Bn | 197.43 Bn |
| 3 | AbbVie | 503.17 Bn | 476.28 Bn | 12.70 Bn | 135.12 Bn |
| 4 | Merck | 365.23 Bn | 319.60 Bn | 12.21 Bn | 129.80 Bn |
| 5 | Novartis Ag | 302.66 Bn | 266.65 Bn | 11.24 Bn | 122.03 Bn |
| 6 | Astrazeneca | 267.39 Bn | 241.08 Bn | 12.86 Bn | 115.83 Bn |
| 7 | Amgen | 241.61 Bn | 197.01 Bn | 7.24 Bn | 95.64 Bn |
| 8 | Gilead Sciences | 194.67 Bn | 168.86 Bn | 6.22 Bn | 49.36 Bn |
| 9 | Pfizer | 172.91 Bn | 119.55 Bn | 10.94 Bn | 201.13 Bn |
| 10 | Alzamend Neuro | 5.31 Mn | -10.16 Mn | - | 8.54 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jul 31, 2026 | 8.54 Mn |
| Apr 30, 2026 | 2.08 Mn |
| Jan 31, 2026 | 4.04 Mn |
| Oct 31, 2025 | 5.09 Mn |
| Jul 31, 2025 | 6.33 Mn |
| Apr 30, 2025 | 4.60 Mn |
| Jan 31, 2025 | 4.18 Mn |
| Oct 31, 2024 | 5.01 Mn |
| Jul 31, 2024 | 1.67 Mn |
| Apr 30, 2024 | 631,588.00 |
| Jan 31, 2024 | 782,636.00 |
| Oct 31, 2023 | 983,597.00 |
| Jul 31, 2023 | 2.63 Mn |
| Apr 30, 2023 | 5.92 Mn |
| Jan 31, 2023 | 8.50 Mn |
| Oct 31, 2022 | 10.42 Mn |
| Jul 31, 2022 | 12.21 Mn |
| Apr 30, 2022 | 14.52 Mn |
| Jan 31, 2022 | 12.43 Mn |
| Oct 31, 2021 | 14.50 Mn |
API Access
Alzamend Neuro Liabilities and Shareholders Equity API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=liabilities-and-shareholders-equity&ticker=ALZN&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "liabilities-and-shareholders-equity", "ticker": "ALZN", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=liabilities-and-shareholders-equity&ticker=ALZN&period=max&api_key=YOUR_API_KEY");
const data = await res.json();